ABSTRACT
Objective To observe the clinical efficacy of point injection of spleen polypeptides in the treat-ment of acute exacerbation of chronic obstructive pulmonary disease(AECOPD).Methods Totally 60 patients with AECOPD were randomly divided into the observation group and the control group,30 cases in each group.Based on conventional treatment,the observation group was treated by point injection of spleen polypeptides,4ml for each time, 1 time a day;and the control group was given equivalent volume of spleen polypeptides by intramuscular injection.The treatment lasted two weeks.The clinical efficacy,PCT,inflammatory and ADRs of patients in the two groups were observed.Results In 7 days of treatment,the clinical efficacy was 87% in the observation group,which was better than 60% of the control group (χ2 =5.45,P=0.019).PCT,interleukin-6(IL-6),interleukin-8(IL-8),tumor necrosis factor-α(TNF -α)of the observation group and the control group were (1.84 ±1.48)ng/mL and (2.21 ±1.75)ng/mL,(32.54 ±6.62)ng/L and (38.94 ±5.69)ng/L,(31.51 ±6.03)ng/L and (36.75 ± 7.95)ng/L,(45.90 ±4.40)ng/L and (51.53 ±2.21)ng/L respectively,which were lower than before treatment (t=12.76 and 15.25,13.23 and -8.42,-10.43 and 5.78,25.04 and 26.95,all P<0.01),which of the obser-vation group were lower than the control group(t=-2.84,4.01,-2.74,-6.27,all P<0.01).After treatment, PCT,IL-6,IL-8,TNF-αof the observation group and the control group were (1.05 ±0.74)ng/mL and (1.38 ± 0.87)ng/mL,(26.89 ±3.57)ng/L and (32.44 ±5.96)ng/L,(21.40 ±3.41)ng/L and (27.71 ±5.50)ng/L, (32.29 ±2.40)ng/L and (39.77 ±2.57)ng/L respectively,which were lower than before treatment(t=22.40 and 22.44,23.10 and -11.96,21.40 and 12.66,48.94 and 38.81,all P<0.01),which of the observation group were lower than the control group(t=-4.09,-4.26,-5.29,-11.68,all P<0.01).No obvious side effect was found in the two groups in the treatment and followed-up period.Conclusion Point injection of spleen polypeptides can effectively reduce the inflammatory response in patients with AECOPD,improve clinical outcomes,shorten course of treatment,has better clinical value.